Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Brands
63,7
%
| 9 890 | 60,8 % | 9 801 | 63,7 % | -0.90% |
Generics
36,3
%
| 5 015 | 30,8 % | 5 588 | 36,3 % | +11.42% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Developed Markets
37,0
%
| 5 844 | 35,9 % | 5 700 | 37,0 % | -2.46% |
United States
23,1
%
| 3 947 | 24,3 % | 3 552 | 23,1 % | -10.00% |
Emerging Markets
16,6
%
| 2 637 | 16,2 % | 2 552 | 16,6 % | -3.24% |
China
12,3
%
| 1 951 | 12,0 % | 1 889 | 12,3 % | -3.19% |
Japan, Australia and New Zealand
9,3
%
| 1 634 | 10,0 % | 1 425 | 9,3 % | -12.81% |
Greater China
1,8
%
| 250 | 1,5 % | 271 | 1,8 % | +8.60% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Scott Smith
CEO | Chief Executive Officer | 61 | 29.12.22 |
Abhijit Barve
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | 16.11.20 | |
David Bayles
CMP | Compliance Officer | - | 16.11.20 |
Chief Tech/Sci/R&D Officer | - | - | |
Philippe Martin
CTO | Chief Tech/Sci/R&D Officer | - | 15.12. |
Rajiv Malik
BRD | Director/Board Member | 63 | 16.11.20 |
Investor Relations Contact | - | 01.11.20 | |
Bill Szablewski
IRO | Public Communications Contact | - | 16.11.20 |
Burt Park
LAW | General Counsel | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Melina Higgins
CHM | Chairman | 56 | 16.11.20 |
Mark Parrish
BRD | Director/Board Member | 68 | 16.11.20 |
Harry Korman
BRD | Director/Board Member | 66 | 16.11.20 |
James Kilts
BRD | Director/Board Member | 76 | 16.11.20 |
Elisha Finney
BRD | Director/Board Member | 62 | 29.12.22 |
Robert Coury
BRD | Director/Board Member | 63 | 16.11.20 |
Rajiv Malik
BRD | Director/Board Member | 63 | 16.11.20 |
Scott Smith
CEO | Chief Executive Officer | 61 | 29.12.22 |
JoEllen Dillon
BRD | Director/Board Member | 60 | 16.11.20 |
Richard Mark
BRD | Director/Board Member | 70 | 16.11.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 208 808 670 | 1 183 377 645 ( 97,90 %) | 21 239 521 ( 1,757 %) | 97,90 % |
Unternehmenskontakt
Viatris, Inc.
Robert J. Coury Global Center 1000 Mylan Boulevard
15317, Canonsburg
+724 514 1800
http://www.viatris.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Utah Acquisition Sub, Inc.
| |
Biosimilars Newco Ltd.
Biosimilars Newco Ltd. Chemicals: SpecialtyProcess Industries Part of Viatris, Inc., Biosimilars Newco Ltd. is a British company that manufactures organic chemicals. The private company is located in the UK. |
Chemicals: Specialty
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+24.60% | 672 Mrd. | |
+24.08% | 550 Mrd. | |
-5.63% | 351 Mrd. | |
+15.37% | 317 Mrd. | |
+7.38% | 292 Mrd. | |
+3.26% | 211 Mrd. | |
+0.78% | 203 Mrd. | |
-9.69% | 144 Mrd. | |
-6.63% | 141 Mrd. |